These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 1695256)

  • 1. Antibody responses of humans and nonhuman primates to individual antigenic sites of the hemagglutinin-neuraminidase and fusion glycoproteins after primary infection or reinfection with parainfluenza type 3 virus.
    van Wyke Coelingh KL; Winter CC; Tierney EL; Hall SL; London WT; Kim HW; Chanock RM; Murphy BR
    J Virol; 1990 Aug; 64(8):3833-43. PubMed ID: 1695256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigenic and functional organization of human parainfluenza virus type 3 fusion glycoprotein.
    van Wyke Coelingh K; Tierney EL
    J Virol; 1989 Jan; 63(1):375-82. PubMed ID: 2462062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extensive antigenic diversity among human parainfluenza type 2 virus isolates and immunological relationships among paramyxoviruses revealed by monoclonal antibodies.
    Tsurudome M; Nishio M; Komada H; Bando H; Ito Y
    Virology; 1989 Jul; 171(1):38-48. PubMed ID: 2545038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity.
    Spriggs MK; Murphy BR; Prince GA; Olmsted RA; Collins PL
    J Virol; 1987 Nov; 61(11):3416-23. PubMed ID: 2822951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with a human parainfluenza virus type 3 chimeric FHN glycoprotein formulated with a combination adjuvant induces protective immunity.
    Garg R; Brownlie R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Vaccine; 2017 Dec; 35(51):7139-7146. PubMed ID: 29153777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys.
    Tang RS; Mahmood K; Macphail M; Guzzetta JM; Haller AA; Liu H; Kaur J; Lawlor HA; Stillman EA; Schickli JH; Fouchier RA; Osterhaus AD; Spaete RR
    Vaccine; 2005 Feb; 23(14):1657-67. PubMed ID: 15705469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody response in children to antigen sites on human PIV-3 HN: correlation with known epitopes mapped by monoclonal antibodies.
    Henrickson KJ; Portner A
    Vaccine; 1990 Feb; 8(1):75-80. PubMed ID: 1690489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquisition of serum antibodies to specific viral glycoproteins of parainfluenza virus 3 in children.
    Kasel JA; Frank AL; Keitel WA; Taber LH; Glezen WP
    J Virol; 1984 Dec; 52(3):828-32. PubMed ID: 6092715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigenic and structural properties of the hemagglutinin-neuraminidase glycoprotein of human parainfluenza virus type 3: sequence analysis of variants selected with monoclonal antibodies which inhibit infectivity, hemagglutination, and neuraminidase activities.
    van Wyke Coelingh KL; Winter CC; Jorgensen ED; Murphy BR
    J Virol; 1987 May; 61(5):1473-7. PubMed ID: 2437318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigenic variation of human and bovine parainfluenza virus type 3 strains.
    Klippmark E; Rydbeck R; Shibuta H; Norrby E
    J Gen Virol; 1990 Jul; 71 ( Pt 7)():1577-80. PubMed ID: 1695673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates.
    Tao T; Skiadopoulos MH; Davoodi F; Riggs JM; Collins PL; Murphy BR
    J Virol; 2000 Jul; 74(14):6448-58. PubMed ID: 10864657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naturally occurring human parainfluenza type 3 viruses exhibit divergence in amino acid sequence of their fusion protein neutralization epitopes and cleavage sites.
    Coelingh KV; Winter CC
    J Virol; 1990 Mar; 64(3):1329-34. PubMed ID: 1689394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effects of monoclonal antibodies against parainfluenza virus type 3-induced brain infection in hamsters.
    Rydbeck R; Löve A; Norrby E
    J Gen Virol; 1988 May; 69 ( Pt 5)():1019-24. PubMed ID: 2836547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conserved epitopes on the hemagglutinin-neuraminidase proteins of human and bovine parainfluenza type 3 viruses: nucleotide sequence analysis of variants selected with monoclonal antibodies.
    Coelingh KJ; Winter CC; Murphy BR; Rice JM; Kimball PC; Olmsted RA; Collins PL
    J Virol; 1986 Oct; 60(1):90-6. PubMed ID: 2427750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional and structural basis of human parainfluenza virus type 3 neutralization with human monoclonal antibodies.
    Suryadevara N; Otrelo-Cardoso AR; Kose N; Hu YX; Binshtein E; Wolters RM; Greninger AL; Handal LS; Carnahan RH; Moscona A; Jardetzky TS; Crowe JE
    Nat Microbiol; 2024 Aug; 9(8):2128-2143. PubMed ID: 38858594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies reveal extensive antigenic differences between the hemagglutinin-neuraminidase glycoproteins of human and bovine parainfluenza 3 viruses.
    Ray R; Compans RW
    Virology; 1986 Jan; 148(1):232-6. PubMed ID: 2417412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with vaccinia virus recombinants that express the surface glycoproteins of human parainfluenza virus type 3 (PIV3) protects patas monkeys against PIV3 infection.
    Spriggs MK; Collins PL; Tierney E; London WT; Murphy BR
    J Virol; 1988 Apr; 62(4):1293-6. PubMed ID: 2831389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates.
    Schmidt AC; McAuliffe JM; Huang A; Surman SR; Bailly JE; Elkins WR; Collins PL; Murphy BR; Skiadopoulos MH
    J Virol; 2000 Oct; 74(19):8922-9. PubMed ID: 10982335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maternal vaccination with a novel chimeric glycoprotein formulated with a polymer-based adjuvant provides protection from human parainfluenza virus type 3 in newborn lambs.
    Garg R; Latimer L; Gomis S; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Antiviral Res; 2019 Feb; 162():54-60. PubMed ID: 30550799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
    Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.